1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
SQZ Biotechnologies Company

SQZ Biotechnologies Company

SQZ
SQZ Biotechnologies CompanyUS flagNew York Stock Exchange
0.44
USD
+0.17
- -
12.83MMarket Cap
SQZ Biotechnologies Company
SQZ
(New York Stock Exchange)

Recent

price

0.44

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available
Similar Companies
FamiCord AG (V3V.DE)
TetraLogic Pharmaceuticals Corporation (TLOG)
CymaBay Therapeutics, Inc. (CBAY)
Unity Biotechnology, Inc. (UNBX)
Affimed N.V. (AFMDQ)
4D Molecular Therapeutics, Inc. (FDMT)
Business
SQZ Biotechnologies Company is a clinical-stage biotechnology firm specializing in the development of cell therapies targeting cancer, autoimmune diseases, infectious diseases, and other serious medical conditions. The company’s proprietary Cell Squeeze® technology enables intracellular delivery of therapeutic cargo into various patient cell types by mechanically disrupting the cell membrane through a gentle squeezing process, facilitating the engineering of immune cells for therapeutic purposes. Its main product platforms include SQZ Enhanced Antigen Presenting Cells (eAPC), SQZ Activating Antigen Carrier (AAC), and SQZ Tolerizing Antigen Carrier (TAC), used to develop therapies in immune activation for oncology and infectious diseases as well as immune tolerance for autoimmune disorders. Lead clinical candidates involve therapies targeting HPV16+ advanced or metastatic solid tumors including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancers. Founded in 2013 and headquartered in Watertown, Massachusetts, SQZ Biotechnologies also focuses on integrated point-of-care cell therapy manufacturing systems designed to streamline and accelerate the production of cell therapies, significantly reducing processing times and operator hours compared to traditional cleanroom methods. The company operates primarily in the United States but its technology was backed by major collaborations, including a significant $500 million partnership established with Roche in 2015 to develop B cell therapy platforms for oncology indications. In early 2024, SQZ Biotechnologies underwent substantial operational changes with the acquisition of substantially all its assets by Canada-based STEMCELL Technologies. This acquisition included SQZ’s extensive portfolio of over 400 patents and trademarks, proprietary equipment, and a head license with the Massachusetts Institute of Technology. STEMCELL Technologies aims to leverage SQZ's Cell Squeeze® technology to enhance its own cell therapy instrument offerings and support the development and delivery of novel cell therapies in cancer and other disease areas. This strategic shift marks the transition of SQZ’s cell therapy science and assets into STEMCELL’s broader biotechnological capabilities, representing a major business reorganization and expansion in the cell therapy landscape. SQZ Biotechnologies' innovative approach to cell engineering and its high-impact collaborations have positioned it as a pioneer in cell therapy development, with a strong focus on creating well-tolerated, efficacious immune-modulating treatments through advanced delivery technologies and manufacturing solutions. The company has been actively advancing clinical trials, with ongoing Phase I studies for its SQZ-PBMC-HPV and related product candidates in the oncology field. Overall, SQZ Biotechnologies operates within the healthcare biotechnology sector, with core expertise in immune cell engineering, therapeutic development, and manufacturing innovation, fostering advancements in immuno-oncology and autoimmune disease treatment paradigms before its strategic asset acquisition and integration by STEMCELL Technologies in 2024. The company originally emerged from MIT research and received venture backing from Polaris Partners and others during its development phase.

Company News

Company News APIChatGPT